DBPR376-Targeting Small Molecule Mertansine Conjugate for Cancer Treatment(SMDC)
In order to address the impact of side effects on the quality of life of cancer patients during chemotherapy, a new generation of small molecule warhead-drug conjugate technology has been developed. National Health Research Institutes (NHRI) develop the peptide drug conjugate DBPR376 utilizes -Novel Luteinizing Hormone-Releasing Hormone Receptor (LHRH) as the targeting motif to detect signals released by cancer cells and allows accumulation that leads to the increasing cancer drug DM1 concentration in tumors.
法人
GLUT Targeting Small Molecule Drug Conjugation for Cancer Therapy
Novel Small Molecule AXL and MERTK Dual Tyrosine Kinase Inhibitor as A nti-Tumor and Immunomodulatory Agent
A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
Direct Reprogramming of Human Fibroblasts into Retinal Progenitor Cells by Small Molecules to Treat Photoreceptor Degeneration Induced Blindness
Technology maturity：Experiment stage
Exhibiting purpose：Technology transactions
Trading preferences：Exclusive license/assignment、New products development、Negotiate by self
Coming soon!